Abstract
Magnetic resonance (MR) angiography has significantly reduced the need for diagnostic conventional angiography and is preferred over CT angiography in children because of its lack of ionizing radiation. The availability of gadofosveset trisodium (the only clinically approved blood pool MR contrast agent) has led to an increase in applications of MR for vascular imaging and an improvement in diagnostic quality of MR angiography. Gadofosveset is a gadolinium-based contrast agent that binds reversibly to albumin, resulting in increased paramagnetic effect and longer intravascular residence. This allows for high-resolution arterial and venous MR angiography, assessment of flow characteristics of vascular malformations, dynamic vascular imaging, and multi-station imaging with a single low-dose gadolinium contrast injection. The purpose of this pictorial essay is to facilitate understanding of the kinetics and safety profile of gadofosveset trisodium, discuss technical aspects of imaging, and illustrate advantages and extracardiac applications in pediatric body imaging.
References
U.S. Food and Drug Administration (2010) Highlights of prescribing information: Ablavar. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021711s003lbl.pdf. Accessed 11 Aug 2014
Parmelee DJ, Walovitch RC, Ouellet HS et al (1997) Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol 32:741–747
Grist TM, Korosec FR, Peters DC et al (1998) Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 207:539–544
Henness S, Keating GM (2006) Gadofosveset. Drugs 66:851–857
Caravan P, Cloutier NJ, Greenfield MT et al (2002) The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 124:3152–3162
Perreault P, Edelman MA, Baum RA et al (2003) MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology 229:811–820
Bremerich J, Bilecen D, Reimer P (2007) MR angiography with blood pool contrast agents. Eur Radiol 17:3017–3024
Shamsi K, Yucel EK, Chamberlin P (2006) A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol 41:822–830
Rigsby C, Popescu A, Boylan E et al (2014) Safety of a blood pool contrast agent in children and young adults. Pediatr Radiol 44:S81
Prince MR, Pearson GD, Zhang HL et al (2010) Advantages of blood pooling in pediatric MR angiography. JACC Cardiovasc Imaging 3:514–516
Zou Z, Zhang HL, Roditi GH et al (2011) Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 4:1206–1216
Sabach AS, Bruno M, Kim D et al (2013) Gadofosveset trisodium: abdominal and peripheral vascular applications. AJR Am J Roentgenol 200:1378–1386
Kim CY, Heye T, Bashir MR et al (2013) Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose. J Comput Assist Tomogr 37:732–736
Goyen M, Edelman M, Perreault P et al (2005) MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 236:825–833
Haneder S, Attenberger UI, Biffar A et al (2011) Gadofosveset: parameter optimization for steady-state imaging of the thoracic and abdominal vasculature. Invest Radiol 46:678–685
Klessen C, Hein PA, Huppertz A et al (2007) First-pass whole-body magnetic resonance angiography (MRA) using the blood-pool contrast medium gadofosveset trisodium: comparison to gadopentetate dimeglumine. Invest Radiol 42:659–664
Maki JH, Wang M, Wilson GJ et al (2009) Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents. J Magn Reson Imaging 30:1085–1092
Hadizadeh DR, Gieseke J, Lohmaier SH et al (2008) Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. Radiology 249:701–711
Vasanawala SS, Chan FP, Newman B et al (2011) Combined respiratory and cardiac triggering improves blood pool contrast-enhanced pediatric cardiovascular MRI. Pediatr Radiol 41:1536–1544
Naehle CP, Kaestner M, Muller A et al (2010) First-pass and steady-state MR angiography of thoracic vasculature in children and adolescents. JACC Cardiovasc Imaging 3:504–513
Boettcher J, Pfeil A, Wolf G et al (2013) Magnetic resonance venography of the upper venous system with blood pool contrast agent: comparison of two different T1-weighted sequences. Clin Imaging 37:245–250
Huang SY, Kim CY, Miller MJ et al (2013) Abdominopelvic and lower extremity deep venous thrombosis: evaluation with contrast-enhanced MR venography with a blood-pool agent. AJR Am J Roentgenol 201:208–214
Pfeil A, Betge S, Poehlmann G et al (2012) Magnetic resonance VIBE venography using the blood pool contrast agent gadofosveset trisodium — an interrater reliability study. Eur J Radiol 81:547–552
Ghanouni P, Walters SG, Vasanawala SS (2012) Rapid MR venography in children using a blood pool contrast agent and multi-station fat-water-separated volumetric imaging. Pediatr Radiol 42:242–248
Stein PD, Chenevert TL, Fowler SE et al (2010) Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 152:434–443
Hansch A, Betge S, Poehlmann G et al (2011) Combined magnetic resonance imaging of deep venous thrombosis and pulmonary arteries after a single injection of a blood pool contrast agent. Eur Radiol 21:318–325
Pressacco J, Papas K (2012) Gadofosveset-enhanced magnetic resonance angiography as a means of evaluating pulmonary arteriovenous malformation: a case report. Magn Reson Imaging 30:886–888
Williams J, Vasanawala SS (2011) Active gastrointestinal hemorrhage identification by blood pool contrast-enhanced magnetic resonance angiography. Pediatr Radiol 41:1198–1200
Jacobi B, Schubert T, Partovi S et al (2012) Gadofosveset — a blood pool contrast agent used with MRI to detect obscure gastrointestinal bleeding: a case report. Am J Gastroenterol 107:1107–1109
Semionov A, Pressacco J (2011) Gadofosveset-enhanced 4D magnetic resonance angiography as a means of localizing the site of post aortic graft leak. Magn Reson Imaging 29:300–302
Milot L, Haider M, Foster L et al (2012) Gadofosveset trisodium in the investigation of focal liver lesions in noncirrhotic liver: early experience. J Magn Reson Imaging 36:738–742
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
CME activity
This article has been selected as the CME activity for the current month. Please visit the SPR Web site at www.pedrad.org on the Education page and follow the instructions to complete this CME activity.
Rights and permissions
About this article
Cite this article
Farmakis, S.G., Khanna, G. Extracardiac applications of MR blood pool contrast agent in children. Pediatr Radiol 44, 1598–1609 (2014). https://doi.org/10.1007/s00247-014-3167-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-014-3167-x